Kinase Inhibitors

Kinase Inhibitor

Cytochrome P450 3A Inhibitors

Breast Neoplasms

<section class="Section" data-sectioncode="34089-3"><a name="section-9"></a><h1>11     DESCRIPTION</h1>KISQALI (ribociclib) is a kinase inhibitor.The chemical name of ribociclib succinate is: Butanedioic acid—7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl) pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide (1/1).Ribociclib succinate is a light yellow to yellowish brown crystalline powder. The molecular formula for ribociclib succinate is C23H30N8O·C4H6O4 and the molecular weight is 552.64 g/mol (Free base: 434.55 g/mol). The chemical structure of ribociclib is shown below:<img alt="The Following chemical structure of KISQALI film-coated tablets are supplied for oral administration and contain 200 mg of ribociclib free base (equivalent to 254.40 mg ribociclib succinate). The tablets also contain colloidal silicon dioxide, crospovidone, hydroxypropylcellulose, magnesium stearate and microcrystalline cellulose. The film-coating contains iron oxide black, iron oxide red, lecithin (soya), polyvinyl alcohol (partially hydrolysed), talc, titanium dioxide, and xanthan gum as inactive ingredients. " src="kisqali-01.jpg"/>KISQALI film-coated tablets are supplied for oral use and contain 200 mg of ribociclib free base (equivalent to 254.40 mg ribociclib succinate). The tablets also contain colloidal silicon dioxide, crospovidone, hydroxypropylcellulose, magnesium stearate and microcrystalline cellulose. The film-coating contains iron oxide black, iron oxide red, lecithin (soya), polyvinyl alcohol (partially hydrolysed), talc, titanium dioxide, and xanthan gum as inactive ingredients.</section>

KISQALI

ribociclib

ribociclib 200 MG Oral Tablet

Kisqali

ribociclib 200 MG Oral Tablet [Kisqali]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio


Kisqali is a medication that inhibits the growth and spread of cancer cells in the body. It is used to treat hormone-related breast cancer in women and is only prescribed if the cancer tests negative for the protein HER2, which can speed up cancer growth. Kisqali is used when the cancer has progressed or spread to other parts of the body after other treatments.

Kisqali is FDA-approved for the following indications: HR+ HER2- advanced or metastatic breast cancer. 

Report Adverse Event 

Prescribing Information - Kisqali 

Medication Guide - Kisqali 

Prescribing Information - Kisqali Femara Copack

Medication Guide - Kisqali Femara Copack 

Submit MSL Request 

Pharmacy List 

Coverage Authorization Request 

Coverage Authorization Appeals 

Enroll in Patient Savings Porgam - Kisqali 

Enroll in Patient Savings Program - Kisqali Femara Copack 

Other HCP Resources: Video Library 

Other HCP Resources 

Bridge Program 

One Free Treatment Cycle 

Managing Your Day-To-Day Resources 

Doctor Discussion Guide 

About Kisqali 

Taking Kisqali 

Side Effects 

Managing Side Effects 

FAQs: Metastatic Breast Cancer 

Novartis Patient Navigator Program

Kisqali Care

Getting Started With Treatment

Instructions For Use: Metastatic Breast Cancer 

Kisqali Start Form